homepage-top-section

The lipid-peptide analog, OK-101 comprises a 12 amino acid peptide sequence, an anchoring lipid domain, and a linker component. It has been developed using a new membrane-anchored peptide

Scemblix specifically targets the ABL myristoyl pocket, which is also called as a STAMP inhibitor in scientific literature. It provides a new treatment approach for patients experiencing intolerance

Under the terms of the deal, the company will facilitate access to its monkeypox vaccines in Latin America and the Caribbean, as well as the countries that participate

The monoclonal antibody is being investigated to reduce the risk of major thrombotic cardiovascular events in ESRD patients MK-2060 is a new Factor XI inhibitor and has been designed to

The vaccine has been approved for preventing dengue disease in people aged six years to 45 years. Qdenga has been developed based on a live-attenuated dengue serotype 2

Auvelity is claimed to be the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist with multimodal activity that has been approved to treat MDD. It is said

The regulator has approved Pepaxti in combination with dexamethasone to treat adult multiple myeloma patients who have received at least three lines of therapies previously, whose disease is

The latest move follows a definitive merger agreement signed by the companies for the transaction in June. As announced previously, Bristol Myers Squibb purchased all outstanding shares of

Flagship Pioneering took part in the financing round, which has also seen participation from new investors, including Bluwave Capital, Qatar Investment Authority (QIA), Stage 1 Ventures, and Samsung